Contact:
4008465777
Tonghua Dongbao gets the nod for clinical trials on world’s first triple SGLT1/SGLT2/DPP4 inhibitor
Date：2021-06-28
Author：東寶
Views：210
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. (Dongbao Zixing), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. (the “Company” or “Tonghua Dongbao”), received the notice of approval from the National Medical Products Administration (NMPA) for the clinical trial of its triple-target inhibitor (THDBH101 Tablets/WXSHC071 Tablets) the other day.
This is the world’s first combined SGLT1/SGLT2/DPP4 therapy for type 2 diabetes. The SGLT1 inhibitor can further lower the glucose by reducing and delaying intestinal glucose absorption on top of SGLT2 inhibition while the DPP4 inhibitor can protect cardiac, renal, and vascular systems. With multiple mechanisms of action, the product can bring clinical benefits in addition to glucose lowering. The existing combo medications include Steglujan, a combination of ertugliflozin (an SGLT2 inhibitor) and sitagliptin (a DPP-4 inhibitor) jointly developed by Pfizer and Merck Sharp & Dohme, and Sogliptin, a dual SGLT1 and SGLT2 inhibitor developed by Lexicon. Neither of them is available in China.
As the pharmaceutical industry enters a new era, research innovation is imperative. With the triple-target inhibitor approved for clinical trials, Tonghua Dongbao takes its R&D of novel drugs for diabetes to a new level.
Since the beginning of this year, the Company has been establishing its presence in the field of novel drug development. It established a novel drug R&D center in Hangzhou in February 2021, and signed a strategic cooperation memorandum on three novel drug projects with WuXi AppTec in March 2021, to launch comprehensive cooperation on novel drug development through drug co-development, drug R&D services, and international cooperation. This is a big step forward for the Company in novel drug development, which further expands its pharmaceutical R&D portfolios for the treatment of diabetes. All of these embody the Company’s philosophy of "Establishing a Global Brand Through Consistent Innovation" and its commitment to technological innovation.
Tonghua Dongbao will continue to enhance its R&D platform and innovation system and focus on drug development for diabetes and other major endocrine diseases. As China enacts policies to encourage drug innovation, the Company will double down on technological innovation and new drug R&D, in an effort to build a world-class R&D and commercialization platform. In the new era, Tonghua Dongbao will continue its efforts to achieve its original aspiration, to mark the 100th anniversary of the founding of the Communist Party of China with great business performance.
